WO2003062241A8 - Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function - Google Patents

Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function

Info

Publication number
WO2003062241A8
WO2003062241A8 PCT/US2002/040598 US0240598W WO03062241A8 WO 2003062241 A8 WO2003062241 A8 WO 2003062241A8 US 0240598 W US0240598 W US 0240598W WO 03062241 A8 WO03062241 A8 WO 03062241A8
Authority
WO
WIPO (PCT)
Prior art keywords
hormone receptor
succinimidecompounds
modulators
analogs
nuclear hormone
Prior art date
Application number
PCT/US2002/040598
Other languages
French (fr)
Other versions
WO2003062241A1 (en
Inventor
Mark E Salvati
James Aaron Balog
Dacia A Pickering
Soren Giese
Aberra Fura
Wenying Li
Ramesh N Patel
Ronald L Hanson
Toomas Mitt
Jacques Roberge
James R Corte
Steven H Spergel
Richard A Rampulla
Raj Misra
Hai-Yun Xiao
Original Assignee
Bristol Myers Squibb Co
Mark E Salvati
James Aaron Balog
Dacia A Pickering
Soren Giese
Aberra Fura
Wenying Li
Ramesh N Patel
Ronald L Hanson
Toomas Mitt
Jacques Roberge
James R Corte
Steven H Spergel
Richard A Rampulla
Raj Misra
Hai-Yun Xiao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA04005876A priority Critical patent/MXPA04005876A/en
Priority to CA002471342A priority patent/CA2471342A1/en
Priority to HU0402554A priority patent/HUP0402554A3/en
Priority to AU2002361785A priority patent/AU2002361785B2/en
Priority to JP2003562118A priority patent/JP2005523257A/en
Priority to BR0215281-9A priority patent/BR0215281A/en
Priority to HR20040567A priority patent/HRP20040567A2/en
Priority to SI200230767T priority patent/SI1458723T1/en
Priority to KR10-2004-7009794A priority patent/KR20040086248A/en
Priority to DK02797421T priority patent/DK1458723T3/en
Priority to DE60229435T priority patent/DE60229435D1/en
Priority to EP02797421A priority patent/EP1458723B1/en
Application filed by Bristol Myers Squibb Co, Mark E Salvati, James Aaron Balog, Dacia A Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh N Patel, Ronald L Hanson, Toomas Mitt, Jacques Roberge, James R Corte, Steven H Spergel, Richard A Rampulla, Raj Misra, Hai-Yun Xiao filed Critical Bristol Myers Squibb Co
Priority to IL16254702A priority patent/IL162547A0/en
Priority to NZ533471A priority patent/NZ533471A/en
Priority to UA20040705945A priority patent/UA78265C2/en
Publication of WO2003062241A1 publication Critical patent/WO2003062241A1/en
Priority to IS7324A priority patent/IS7324A/en
Priority to NO20043068A priority patent/NO20043068L/en
Publication of WO2003062241A8 publication Critical patent/WO2003062241A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Fused cyclic compounds method of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
PCT/US2002/040598 2001-12-19 2002-12-18 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function WO2003062241A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CA002471342A CA2471342A1 (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
HU0402554A HUP0402554A3 (en) 2001-12-19 2002-12-18 Condensated heterocyclic succinimide compounds, their use, process for the preparation of some of them and pharmaceutical compositions containing the compounds
AU2002361785A AU2002361785B2 (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function
JP2003562118A JP2005523257A (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimide compounds and analogs thereof that are modulators of nuclear hormone receptor function
BR0215281-9A BR0215281A (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimide compounds and their analogues, modulators of nuclear hormone receptor function
HR20040567A HRP20040567A2 (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
SI200230767T SI1458723T1 (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
DK02797421T DK1458723T3 (en) 2001-12-19 2002-12-18 Condensed heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
KR10-2004-7009794A KR20040086248A (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
MXPA04005876A MXPA04005876A (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function.
EP02797421A EP1458723B1 (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
DE60229435T DE60229435D1 (en) 2001-12-19 2002-12-18 CONDENSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND THEIR ANALOGUES, MODULATORS OF THE FUNCTION OF NUCLEAR HORMONE RECEPTORS
IL16254702A IL162547A0 (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimide derivatives and pharmaceutical compositions containing the same
NZ533471A NZ533471A (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
UA20040705945A UA78265C2 (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
IS7324A IS7324A (en) 2001-12-19 2004-06-18 Synchronous heterocyclic succinimide compounds and their analogues, configured for nuclear hormone receptor activity
NO20043068A NO20043068L (en) 2001-12-19 2004-07-16 Condensed heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2511601A 2001-12-19 2001-12-19
US10/025,116 2001-12-19

Publications (2)

Publication Number Publication Date
WO2003062241A1 WO2003062241A1 (en) 2003-07-31
WO2003062241A8 true WO2003062241A8 (en) 2004-10-21

Family

ID=27609007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/040598 WO2003062241A1 (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function

Country Status (31)

Country Link
EP (1) EP1458723B1 (en)
JP (1) JP2005523257A (en)
KR (1) KR20040086248A (en)
CN (1) CN1589271A (en)
AR (1) AR037950A1 (en)
AT (1) ATE411319T1 (en)
AU (1) AU2002361785B2 (en)
BR (1) BR0215281A (en)
CA (1) CA2471342A1 (en)
CO (1) CO5640082A2 (en)
DE (1) DE60229435D1 (en)
DK (1) DK1458723T3 (en)
ES (1) ES2314127T3 (en)
GE (1) GEP20063817B (en)
HR (1) HRP20040567A2 (en)
HU (1) HUP0402554A3 (en)
IL (1) IL162547A0 (en)
IS (1) IS7324A (en)
MX (1) MXPA04005876A (en)
NO (1) NO20043068L (en)
NZ (1) NZ533471A (en)
PL (1) PL370904A1 (en)
PT (1) PT1458723E (en)
RU (1) RU2330038C2 (en)
SI (1) SI1458723T1 (en)
TW (1) TWI263640B (en)
UA (1) UA78265C2 (en)
UY (1) UY27595A1 (en)
WO (1) WO2003062241A1 (en)
YU (1) YU53604A (en)
ZA (1) ZA200404812B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291637B2 (en) 2001-12-19 2007-11-06 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
US7470797B2 (en) 2001-06-20 2008-12-30 Bristol-Myers Squibb Company Fused heterocyclic imido and amido compounds

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202264B2 (en) 2003-01-31 2007-04-10 Isis Pharmaceuticals, Inc. Supports for oligomer synthesis
FR2860793A1 (en) * 2003-10-14 2005-04-15 Entomed New norcantharidin derivatives e.g. used for treating cancer, neurodegenerative diseases, restenosis, diabetes, asthma and bacterial and fungal infections
EP1692139B1 (en) * 2003-11-13 2013-02-13 Isis Pharmaceuticals, Inc. 5,6 -dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7605264B2 (en) 2004-01-16 2009-10-20 Bristol-Myers Squibb Company Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7569689B2 (en) 2004-01-16 2009-08-04 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en) 2004-01-16 2008-02-05 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
US7625921B2 (en) 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AU2005223481A1 (en) * 2004-03-17 2005-09-29 Pfizer Products Inc. Novel benzyl(idene)-lactam derivatives
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7642273B2 (en) 2005-01-13 2010-01-05 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7411071B2 (en) 2005-01-13 2008-08-12 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
ATE478852T1 (en) * 2005-09-09 2010-09-15 Schering Corp NEW 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLOÄ1,5-AÜPYRIDINES, PYRAZOLOÄ1,5-CÜPYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZOÄ1,2- AÜPYRIDINES, AND IMIDAZOÄ1,5-AÜPYRAZINE COMPOUNDS AS INHIBITORS OF CYCLIN-DEPENDENT KINASE
WO2008042571A2 (en) 2006-09-29 2008-04-10 Smithkline Beecham Corporation Substituted indole compounds
WO2008157291A2 (en) * 2007-06-15 2008-12-24 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION
EP2426117A4 (en) * 2009-04-30 2012-09-19 Sumitomo Chemical Co thiophene
US20120135997A1 (en) 2009-07-17 2012-05-31 Shionogi & Co., Ltd. Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
US20120238533A1 (en) 2009-09-11 2012-09-20 Bayer Pharma Aktiengesellschaft (Heteroarylmethyl) Thiohydantoins as anticancer drugs
CA2786443C (en) 2010-01-14 2018-12-11 Novartis Ag Use of an adrenal hormone-modifying agent
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
US9868748B2 (en) 2013-05-01 2018-01-16 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ROR- γ
JP6156074B2 (en) * 2013-11-08 2017-07-05 住友化学株式会社 Succinimide compounds and uses thereof
HUE045511T2 (en) 2014-02-03 2020-01-28 Vitae Pharmaceuticals Llc Dihydropyrrolopyridine inhibitors of ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3372585B1 (en) * 2014-12-19 2022-03-30 Aragon Pharmaceuticals, Inc. Process for the preparation of a diarylthiohydantoin compound
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2016209349B2 (en) * 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
MA53943A (en) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc ROR-GAMMA MODULATORS
TWI757266B (en) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 Modulators of ror-gamma
ES2922932T3 (en) 2016-12-29 2022-09-21 Enyo Pharma Thiophene derivatives as antiviral agents
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of ror gamma
WO2019023207A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF RORƳ
JP2023518299A (en) * 2020-03-20 2023-04-28 ユニバーシティー オブ サウザン カリフォルニア Androgen receptor modulation by small molecule enantiomers
ES2991366T3 (en) 2020-05-08 2024-12-03 Halia Therapeutics Inc NEK7 kinase inhibitors
CN114848795B (en) * 2021-02-03 2023-04-14 四川大学 Application of RORa protein and its agonist in the preparation of anti-aging medicine
US20250064948A1 (en) * 2022-02-14 2025-02-27 The Johns Hopkins University Gcpii inhibition for the treatment of sarcopenia and aging
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320270A (en) * 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3215597A (en) * 1963-10-30 1965-11-02 Dow Chemical Co Methods and compositions for use in animal husbandry
US3261845A (en) * 1964-07-14 1966-07-19 Dow Chemical Co N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide
US4892943A (en) * 1985-10-16 1990-01-09 American Home Products Corporation Fused bicyclic imides with psychotropic activity
JPS63170383A (en) * 1987-02-26 1988-07-14 Nippon Zeon Co Ltd Alicyclic dicarboxylic acid imide compound
ZA908641B (en) * 1989-10-27 1992-06-24 Du Pont (n-phthalimidoalkyl)piperidines
KR100531967B1 (en) * 1996-10-25 2005-11-30 다이이찌 세이야꾸 가부시기가이샤 Tricyclic amine derivatives, an antimicrobial agent comprising the compound and a process for preparing a quinolone compound
FR2764890B1 (en) * 1997-06-24 1999-08-27 Adir NOVEL CHROMENIC DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2000037472A2 (en) * 1998-12-22 2000-06-29 Eli Lilly And Company Substituted pirroloindoles
US6521753B1 (en) * 2000-05-31 2003-02-18 Johnson & Johnson Vision Care, Inc. Indolinospiropyran compounds and methods for their manufacture
US6960474B2 (en) * 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator
PL361707A1 (en) * 2000-09-19 2004-10-04 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517904B2 (en) 2000-09-19 2009-04-14 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7470797B2 (en) 2001-06-20 2008-12-30 Bristol-Myers Squibb Company Fused heterocyclic imido and amido compounds
US7291637B2 (en) 2001-12-19 2007-11-06 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
US7342034B2 (en) 2001-12-19 2008-03-11 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function

Also Published As

Publication number Publication date
SI1458723T1 (en) 2009-02-28
RU2330038C2 (en) 2008-07-27
GEP20063817B (en) 2006-05-10
TWI263640B (en) 2006-10-11
ES2314127T3 (en) 2009-03-16
RU2004122403A (en) 2005-05-27
EP1458723A1 (en) 2004-09-22
CA2471342A1 (en) 2003-07-31
HUP0402554A2 (en) 2005-03-29
UY27595A1 (en) 2003-07-31
AU2002361785B2 (en) 2008-05-22
BR0215281A (en) 2004-10-19
NO20043068L (en) 2004-09-08
KR20040086248A (en) 2004-10-08
HUP0402554A3 (en) 2009-01-28
EP1458723A4 (en) 2005-12-21
IL162547A0 (en) 2005-11-20
UA78265C2 (en) 2007-03-15
TW200304810A (en) 2003-10-16
EP1458723B1 (en) 2008-10-15
NZ533471A (en) 2007-05-31
CO5640082A2 (en) 2006-05-31
IS7324A (en) 2004-06-18
ATE411319T1 (en) 2008-10-15
MXPA04005876A (en) 2005-05-16
YU53604A (en) 2006-08-17
AR037950A1 (en) 2004-12-22
ZA200404812B (en) 2005-08-26
DK1458723T3 (en) 2009-02-09
PT1458723E (en) 2008-12-26
WO2003062241A1 (en) 2003-07-31
PL370904A1 (en) 2005-05-30
DE60229435D1 (en) 2008-11-27
CN1589271A (en) 2005-03-02
JP2005523257A (en) 2005-08-04
HRP20040567A2 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2003062241A8 (en) Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function
WO2003053358A3 (en) Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
WO2003053354A3 (en) Fused cyclic modulators of nuclear hormone receptor function
MY138531A (en) Fused heterocyclic succinmide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002000653A3 (en) Fused cyclic compounds as modulators of nuclear hormone receptor function
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
IL219397A0 (en) Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
HUP0304055A2 (en) Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
WO2005048935A3 (en) Methods of modulating immunity
IL162185A0 (en) Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
WO2006002102A3 (en) Spirocyclic compounds useful as modulators of nuclear hormone receptor function
IL165012A0 (en) (S)-4-Amino-5-chloro-2-methoxy-N-Ä1-(-tetrahydrofurylcarbonyl)-4-piperidinylmethylÜ-4-piperidinylÜbenzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
IL140140A0 (en) Thyroid hormone analogues and methods for their preparation
MXPA03005980A (en) Compositions for nasal administration of insulin.
HUP0401350A3 (en) Novel imidazopyridine compounds with therapeutic effect, process for their preparation and pharmaceutical compositions containing them
PL366565A1 (en) Fused cyclic modulators of nuclear hormone receptor function
EP1854798A3 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
PL373192A1 (en) Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
MXPA02012015A (en) Ligands of integrin receptors.
HK1068620A (en) Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-536/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 533471

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1687/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 162547

Country of ref document: IL

Ref document number: PA/a/2004/005876

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002797421

Country of ref document: EP

Ref document number: 2004/04812

Country of ref document: ZA

Ref document number: P20040567A

Country of ref document: HR

Ref document number: 200404812

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002361785

Country of ref document: AU

Ref document number: 2471342

Country of ref document: CA

Ref document number: 2003562118

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020047009794

Country of ref document: KR

ENP Entry into the national phase

Ref country code: GE

Ref document number: GE P

WWE Wipo information: entry into national phase

Ref document number: 8309

Country of ref document: GE

Ref document number: 1200400669

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2004122403

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 20028281063

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002797421

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 31/2003 UNDER (71) REPLACE "BRISTOLS-MYERS SQUIBB COMPANY" BY "BRISTOL-MYERS SQUIBB COMPANY"; UNDER (72, 75) REPLACE "PICKERING, DARCIA, A." BY "PICKERING, DACIA, A."

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500877

Country of ref document: PH